Thursday, September 15, 2011
DVS Sciences, which invented and manufactures an instrument enabling biomarker analysis for scientific research, clinical trials and personalized medicine, has raised $14.6 million in series A financing. This is the largest venture-backed series A equity raised in Canada’s life sciences and medical technology fields in recent years, and is almost twice the average series A funding in the U.S., the company said.
The Ontario Institute for Cancer Research (OICR) and DVS Sciences have announced DVS Sciences has completed a $14.6 million series A financing. DVS, a Toronto-based spinoff from the University of Toronto, invented and manufactures instrumentation that enables paradigm-shifting biological research with potential clinical applications that include personalized medicine.